Levinson J E, Baum J, Brewer E, Fink C, Hanson V, Schaller J
J Pediatr. 1977 Nov;91(5):799-804. doi: 10.1016/s0022-3476(77)81045-7.
The Pediatric Rheumatology Collaborative Study Group was established in 1973 to undertake systematic trials of new drugs in the treatment of juvenile rheumatoid arthritis. The first drug evaluated was tolmetin (1-methyl-5-p-toluoylpyrrole-2 acetic acid), a new nonsteroid anti-inflammatory agent. A four-week open trial with 30 patients and a subsequent 12-week double-blind trial against aspirin with 107 patients were conducted. Tolmetin and aspirin had equal anti-inflammatory and analgesic effects in the treatment of JRA. Elevations of transaminase values attributed to aspirin were not found with tolmetin. Adverse effects accompanying administration of tolmetin did not appear to be of major clinical significance.
儿科风湿病协作研究组于1973年成立，旨在对治疗青少年类风湿性关节炎的新药进行系统试验。首个评估的药物是托美丁（1-甲基-5-对甲苯甲酰基吡咯-2-乙酸），一种新型非甾体抗炎药。开展了一项针对30名患者的为期四周的开放试验，以及随后一项针对107名患者与阿司匹林对照的为期12周的双盲试验。在治疗青少年类风湿性关节炎方面，托美丁和阿司匹林具有同等的抗炎和镇痛效果。未发现托美丁会出现阿司匹林所致的转氨酶值升高情况。托美丁给药时伴随的不良反应似乎并无重大临床意义。
